AbstractThe treatment of onychomycosis remains problematic even though there are several potent antifungal agents available for patient use. The aim of this investigation was to understand whether the structural modifications that arise when a patient’s nail become infected plates influences the permeation of drugs into the nail following topical application. It was hoped that through improving understanding of the nail barrier in the diseased state, the development of more effective topical treatments for onychomycosis could be facilitated. The permeation of three compounds with differing hydrophobicities, caffeine, terbinafine and amorolfine (clogD at pH 7.4 of −0.55, 3.72 and 4.49 respectively), was assessed across both healthy and onych...
Onychomycosis is a common fungal nail disease that is difficult to treat topically due to the deep l...
Despite terbinafine being fungicidal against Trichophyton rubrum in standard NCCLS assays and rapidl...
ME1111 is a novel antifungal agent currently under clinical development as a topical onychomycosis t...
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/)...
AbstractThe treatment of onychomycosis remains problematic even though there are several potent anti...
The definitive version can be found at: http://www3.interscience.wiley.com/ Copyright Royal Pharmace...
# The Author(s). This article is published with open access at Springerlink.com2014 Purpose Through ...
Nail fungal infection is often mistakenly considered a minor issue or a purely esthetic problem that...
Topical treatment of onychomycosis is complicated by the structure of the nail, one of the strongest...
Introduction. Targeting drug treatment to fungal infections that reside within or below the nail pla...
Open Access - This article is distributed under the terms of the Creative Commons Attribution Licens...
Onychomycosis constitutes the most common fungal infection of the nail (skin beneath the nail bed) t...
Despite improvements in antifungal strategies, the outcome of treating onychomycoses often remains u...
Turner, R., Weaver, S., Caserta, F., Brown, M B., 'A Novel Vehicle for Enhanced Drug Delivery Across...
A nail patch is an attractive option for the topical treatment of onychomycosis, although no product...
Onychomycosis is a common fungal nail disease that is difficult to treat topically due to the deep l...
Despite terbinafine being fungicidal against Trichophyton rubrum in standard NCCLS assays and rapidl...
ME1111 is a novel antifungal agent currently under clinical development as a topical onychomycosis t...
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/)...
AbstractThe treatment of onychomycosis remains problematic even though there are several potent anti...
The definitive version can be found at: http://www3.interscience.wiley.com/ Copyright Royal Pharmace...
# The Author(s). This article is published with open access at Springerlink.com2014 Purpose Through ...
Nail fungal infection is often mistakenly considered a minor issue or a purely esthetic problem that...
Topical treatment of onychomycosis is complicated by the structure of the nail, one of the strongest...
Introduction. Targeting drug treatment to fungal infections that reside within or below the nail pla...
Open Access - This article is distributed under the terms of the Creative Commons Attribution Licens...
Onychomycosis constitutes the most common fungal infection of the nail (skin beneath the nail bed) t...
Despite improvements in antifungal strategies, the outcome of treating onychomycoses often remains u...
Turner, R., Weaver, S., Caserta, F., Brown, M B., 'A Novel Vehicle for Enhanced Drug Delivery Across...
A nail patch is an attractive option for the topical treatment of onychomycosis, although no product...
Onychomycosis is a common fungal nail disease that is difficult to treat topically due to the deep l...
Despite terbinafine being fungicidal against Trichophyton rubrum in standard NCCLS assays and rapidl...
ME1111 is a novel antifungal agent currently under clinical development as a topical onychomycosis t...